Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...
Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Hosted on MSN23h
Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focusNovo Nordisk (NVO) on Wednesday also launched NovoCare Pharmacy to offer the company’s weight loss drugs for ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback